Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trial

Abstract

Introduction:

Acute urinary retention is one of the most significant complications of benign prostatic hyperplasia. Until now, standard treatments include catheterization and use of α-blockers. Tadalafil has been recently seen to also play a role in the treatment of urinary symptoms caused by benign prostatic hyperplasia. The aim of this study was to survey the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia.

Materials and Methods:

This is a randomized, double-blind placebo-controlled clinical trial. In all, 80 patients with benign prostatic hyperplasia–related acute urinary retention referred to the emergency department of the hospital were divided into two groups of 40 each and randomly assigned to receive either 0.4 mg tamsulosin plus placebo or 0.4 mg tamsulosin plus 10 mg tadalafil daily for 7 days. At the same first visit, the catheter was removed and the ability to void in 24 h and 1 week later was assessed in each group.

Results:

The differences in age, urine retention volume, history of drug use, lower urinary tract symptoms, and previous acute urinary retention were not significant between the two groups (p = 0.619, 0.149, 0.501, 0.284, and 0.371, respectively). After catheter removal, 23 (57.5%) patients in the placebo group and 26 (65%) in the tadalafil group voided successfully at 24 h (p = 0.491). After 1 week, 29 (72.5%) patients taking placebo and 26 (65%) taking tadalafil could void, yet indicating no significant difference (p = 0.469).

Conclusion:

Addition of tadalafil to α-blockers has no significant advantage in improving benign prostatic hyperplasia–related acute urinary retention versus tamsulosin alone.

Keywords

Acute urinary retention benign prostatic hyperplasia tadalafil tamsulosin

Get full access to this article

View all access options for this article.

References

Olesovsky

Kapoor

Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. Ther Adv Urol 2016; 8(4): 257–271.

Zhang

Park

JK.

Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?

World J Nephrol 2015; 4(1): 138–147.

Carson

Rosenberg

Kissel

et al . Tadalafil—a therapeutic option in the management of BPH-LUTS. Int J Clin Pract 2014; 68(1): 94–103.

Kim

T-B

Kim

K-H

Yoon

S-J.

Open-label, intermittent dose, prospective study evaluating the effects of tadalafil on lower urinary tract symptoms and erectile function in patients with benign prostatic hyperplasia: continuation and durability of effects. Int Neurourol J 2010; 14(1): 7–12.

Alsaikhan

Alrabeeah

Carrier

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations. Int J Gen Med 2014; 7: 271–276.

Garcia

Rosen

Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int 2005; 96(9): 1339–1354.

Ugare

Bassey

Udosen

et al . Management of lower urinary retention in a limited resource setting. Ethiop J Health Sci 2014; 24(4): 329–336.

Roehrborn

CG.

The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol 2001; 3(4): 187–192.

Hagiwara

Koie

Iwamura

et al . Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: a single-arm prospective study. Biomed Res Int 2016; 2016: 4975851.

10.

Kara

Yazici

Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?

Urol J 2014; 11(3): 1673–1677.

11.

Oelke

Giuliano

Mirone

et al . Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61(5): 917–925.

12.

Pour Reza

Falahatkar

et al . Survey the addition of sildenafil to alpha-blockers in the management of acute urinary retention related to benign prostatic hyperplasia. J Guilan Univ Med Sci 2009; 17(68): 57–62.

13.

Sharifi

SHH

Mokarrar

Khaledi

et al . Does sildenafil enhance the effect of tamsulosin in relieving acute urinary retention? Int Braz J Urol 2014; 40(3): 373–378.

14.

Giuliano

Kaplan

Cabanis

et al . Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006; 67(6): 1199–1204.